Dare Bioscience Inc (DARE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $12.93M
Last updated: Nov 17, 2026 at 4:33 PM ET
Dare Bioscience Inc (DARE) Statistics
Dare Bioscience (DARE) has a market cap of $12.93M and an enterprise value of $1.40M. It kept -749.82% of revenue as net income over the last 12 months. Its share count is up 36.59% from a year earlier.
Total Valuation
Enterprise value is 89.18% below the market cap, as cash exceeds debt.
| Market Cap | $12.93M |
|---|---|
| Enterprise Value | $1.40M |
| Latest price (Nov 17, 2026) | $0.43 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.3x and 3.2x.
| P/S Ratio | 5.3x |
|---|---|
| Forward P/S | 4.7x |
| P/B Ratio | 3.2x |
Enterprise Valuation
Counting debt and cash, the company is valued at 0.2x free cash flow.
| EV / Sales | 1.0x |
|---|---|
| EV / FCF | 0.2x |
Price Statistics
The stock is down 76.94% over 52 weeks and trades 40.28% below its 50-day average.
| Beta (1Y) | 1.44 |
|---|---|
| 52-Week Change | -76.94% |
| 1-Month Change | -39.24% |
| 3-Month Change | -47.96% |
| 6-Month Change | -80.93% |
| 5-Year Change | -96.01% |
| 10-Year Change | -99.27% |
| Total Return (1Y) | -76.94% |
| Total Return (3Y CAGR) | -52.93% |
| Total Return (5Y CAGR) | -53.27% |
| Max Drawdown (1Y) | -86.88% |
| Max Drawdown (3Y) | -94.14% |
| Sharpe Ratio (1Y) | -1.30 |
| Correlation with SPY (1Y) | 0.18 |
| 50-Day Average | $0.72 |
| 200-Day Average | $1.50 |
| 52-Week Range | $0.58 to $3.78 |
| RSI (14 Days) | 22.5 |
| Average Volume (20 Days) | 181.55K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.23x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.23x |
|---|---|
| Quick Ratio | 1.23x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -451.97% and return on assets is -47.89% over the last 12 months.
| Return on Equity (ROE) | -451.97% |
|---|---|
| Return on Assets (ROA) | -47.89% |
| Return on Capital Employed (ROCE) | -129.85% |
| ROA (5Y Average) | -68.26% |
| Asset Turnover | 0.05x |
Scores
DARE has an Altman Z-Score of -13.69, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -13.69 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $1.41M over the last 12 months.
| Revenue | $1.41M |
|---|---|
| Gross Profit | $372.81K |
| Operating Income | -$10.53M |
| Pretax Income | -$10.89M |
| Net Income | -$10.58M |
| EBITDA | -$8.72M |
| EBIT | -$10.89M |
| Reported EPS (TTM) | -$0.68 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 10.59% of the $22.10M in total assets.
| Cash and Equivalents | $11.53M |
|---|---|
| Total Debt | $0 |
| Net Cash | $11.53M |
| Net Cash Per Share | $0.66 |
| Working Capital | $3.21M |
| Shareholder Equity | $2.34M |
| Book Value Per Share | $0.13 |
| Total Assets | $22.10M |
| Total Liabilities | $19.76M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $489.15K of capital spending, operating cash flow left -$18.19M of free cash flow.
| Operating Cash Flow | -$17.70M |
|---|---|
| Capital Expenditures | $489.15K |
| Free Cash Flow | -$18.19M |
| FCF Per Share | -$0.92 |
| Depreciation and Amortization | $2.17M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -746.14%.
| Gross Margin | 26.42% |
|---|---|
| Operating Margin | -746.14% |
| Pretax Margin | -771.52% |
| Net Margin | -749.82% |
| EBITDA Margin | -617.60% |
| EBIT Margin | -771.52% |
| FCF Margin | -1288.82% |
Dividends and Yields
DARE does not pay a dividend. Its free cash flow yield is -243.37%.
| FCF Yield | -243.37% |
|---|---|
| Buyback Yield | -95.85% |
| Shareholder Yield | -95.85% |
Stock Splits
The last split was a 1-for-12 reverse split on Jul 1, 2024.
| Last Split Date | Jul 1, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:12 |
Analyst Forecast
Consensus estimates put revenue growth at 167.97% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +167.97% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About DARE
What is DARE's market cap?
Dare Bioscience has a market cap of $12.93M. Its enterprise value, which adds debt and subtracts cash, is $1.40M.
How many shares of DARE are outstanding?
Dare Bioscience has 17.42M shares outstanding. The count is up 36.59% from a year earlier.
Does DARE pay a dividend?
No. Dare Bioscience does not pay a dividend.
How much debt does DARE have?
Dare Bioscience has $0 of total debt and $11.53M of cash and equivalents, a net cash position of $11.53M.
DARE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors